CY1124986T1 - Υγρο σκευασμα που περιλαμβανει παεονολη και αποκυνινη - Google Patents

Υγρο σκευασμα που περιλαμβανει παεονολη και αποκυνινη

Info

Publication number
CY1124986T1
CY1124986T1 CY20221100119T CY221100119T CY1124986T1 CY 1124986 T1 CY1124986 T1 CY 1124986T1 CY 20221100119 T CY20221100119 T CY 20221100119T CY 221100119 T CY221100119 T CY 221100119T CY 1124986 T1 CY1124986 T1 CY 1124986T1
Authority
CY
Cyprus
Prior art keywords
apocynine
liquid preparation
preparation containing
containing paeonol
paeonol
Prior art date
Application number
CY20221100119T
Other languages
Greek (el)
English (en)
Inventor
Nicholas John Larkins
Original Assignee
Akl Research&Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akl Research&Development Ltd filed Critical Akl Research&Development Ltd
Publication of CY1124986T1 publication Critical patent/CY1124986T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CY20221100119T 2017-11-23 2022-02-10 Υγρο σκευασμα που περιλαμβανει παεονολη και αποκυνινη CY1124986T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1719464.8A GB2568698A (en) 2017-11-23 2017-11-23 Formulation
PCT/EP2018/082178 WO2019101842A1 (en) 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin

Publications (1)

Publication Number Publication Date
CY1124986T1 true CY1124986T1 (el) 2023-01-05

Family

ID=60950758

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100119T CY1124986T1 (el) 2017-11-23 2022-02-10 Υγρο σκευασμα που περιλαμβανει παεονολη και αποκυνινη

Country Status (21)

Country Link
US (2) US11701325B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019005A1 (cg-RX-API-DMAC7.html)
JP (3) JP7314157B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250013306A (cg-RX-API-DMAC7.html)
CN (2) CN111372572B (cg-RX-API-DMAC7.html)
AU (2) AU2018371165B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082945A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124986T1 (cg-RX-API-DMAC7.html)
DK (1) DK3713546T3 (cg-RX-API-DMAC7.html)
ES (1) ES2906761T3 (cg-RX-API-DMAC7.html)
GB (1) GB2568698A (cg-RX-API-DMAC7.html)
HR (1) HRP20220303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057595T2 (cg-RX-API-DMAC7.html)
LT (1) LT3713546T (cg-RX-API-DMAC7.html)
MX (2) MX393836B (cg-RX-API-DMAC7.html)
PL (1) PL3713546T3 (cg-RX-API-DMAC7.html)
PT (1) PT3713546T (cg-RX-API-DMAC7.html)
RS (1) RS62923B1 (cg-RX-API-DMAC7.html)
SI (1) SI3713546T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200101T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019101842A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation
GB202218160D0 (en) * 2022-12-02 2023-01-18 Akl Res & Development Ltd Formulation
CN119033608B (zh) * 2024-11-01 2025-03-25 深圳杉海创新技术有限公司 一种具有抑菌作用的低共熔溶剂、微脂囊及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) * 1989-05-16 1992-08-10 지구르트 퓌터 약제제
CN100544708C (zh) * 2004-08-18 2009-09-30 上海佰加壹医药有限公司 一种丹皮酚软胶囊及其制备方法
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
GB2463080A (en) * 2008-09-02 2010-03-03 Nicholas John Larkins Pharmaceutical preparation
GB201115757D0 (en) * 2011-09-12 2011-10-26 Akl Inflammatory Ltd Formulation for the treatment of benign prostate hyperplasia
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
GB2547241A (en) * 2016-02-11 2017-08-16 Akl Res & Dev Ltd Anti-inflammatory formulation
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation

Also Published As

Publication number Publication date
NZ764238A (en) 2025-12-19
HRP20220303T1 (hr) 2022-05-13
CN116999417A (zh) 2023-11-07
PT3713546T (pt) 2022-02-02
GB2568698A (en) 2019-05-29
MX2020005313A (es) 2020-08-17
GB201719464D0 (en) 2018-01-10
US20200297628A1 (en) 2020-09-24
LT3713546T (lt) 2022-03-10
JP2023104963A (ja) 2023-07-28
EP3713546B1 (en) 2021-12-08
KR20200090858A (ko) 2020-07-29
JP2025065531A (ja) 2025-04-17
CN111372572B (zh) 2023-08-29
CA3082945A1 (en) 2019-05-31
AU2018371165B2 (en) 2024-02-29
ES2906761T3 (es) 2022-04-20
US20230330017A1 (en) 2023-10-19
CN111372572A (zh) 2020-07-03
MX2022008551A (es) 2022-08-10
JP2021504461A (ja) 2021-02-15
AU2024203514B2 (en) 2026-03-19
HUE057595T2 (hu) 2022-05-28
WO2019101842A1 (en) 2019-05-31
PL3713546T3 (pl) 2022-05-02
AU2024203514A1 (en) 2024-06-20
US11701325B2 (en) 2023-07-18
RS62923B1 (sr) 2022-03-31
SI3713546T1 (sl) 2022-04-29
SMT202200101T1 (it) 2022-03-21
EP3713546A1 (en) 2020-09-30
AU2018371165A1 (en) 2020-05-21
EP4019005A1 (en) 2022-06-29
KR102758107B1 (ko) 2025-01-20
DK3713546T3 (da) 2022-01-31
KR20250013306A (ko) 2025-01-31
JP7314157B2 (ja) 2023-07-25
MX393836B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
IL280354A (en) Compositions comprising circular polyribonucleotides and uses thereof
MA49043A (fr) Formulation stable d'anticorps
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
CY1124427T1 (el) Συνθεση omecamtiv mecarbil
TWD187904S (zh) 追蹤裝置
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12017501915A1 (en) Fertilizer and agrochemical formulation
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
MX2017001512A (es) Compuestos activos hacia bromodominios.
UA115737C2 (uk) Інгібітор меланогенезу, який містить d-пантотеніловий спирт, і косметичний засіб для відбілювання шкіри, який містить такий інгібітор меланогенезу
TWD183792S (zh) 捲尺
CL2017000716A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112015030553A2 (pt) dispositivo para a aplicação de substâncias medicinais líquidas
CL2019001622A1 (es) Pulverizador.
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MX2022008551A (es) Formulacion liquida que comprende paeonol y apocinina.
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
PL3595693T3 (pl) Formulacje i dawkowanie kannabinoidów
IL291356A (en) Agrochemical formulation containing a sulfopolymer
EP4034091B1 (en) LIQUID FORMULATION OF RIFAXIMIN
EP3500916A4 (en) GRAPHIC REPRESENTATION MANAGEMENT
IL271875B (en) Application of totarol and pharmaceutical composition containing totarol